~~<i id='BAE5E9E6E8'><strike id='BAE5E9E6E8'><tt id='BAE5E9E6E8'><pre id='BAE5E9E6E8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：knowledge 2025-09-28 02:27:04 - browse：4

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Eli Lilly to pay $200M for Beam’s stake in gene

knowledge

entertainment

Wikipedia

focus

AdobePresidentBidenorderedthenation’sleadinghealthagenciesonMondaytodevelopaplanforregulatingartific

WSS

Traditional Chinese medicine benefits explored in new JAMA study

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

entertainment

fashion

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Diversifying clinical trials isn't enough to close racial gaps: study

Alkermes shareholders re

'The Exorcist' director William Friedkin dead at 87

Trump demands the U.S. pay no more for drugs than other countries … again

The FDA weighs the risks of candy

Cancer drug shortages should be causing more outrage

The FDA weighs the risks of candy

As demand for Covid shots wanes, Moderna seeks its next success

Biden's order seeks to regulate AI risk without stifling innovation

knowledge

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Emergency medicine has repudiated 'excited delirium.' Now what?

Senate panel to vote on hospitals, PBMs, prisoner care

CDC recommends rationing of RSV shot due to shortages

Trump Jan. 6 attorney John Lauro is ex

entertainment

Wikipedia

focus

focus